Biomea Fusion, Inc.
Biomea Fusion, Inc. (BMEA): 4 pipeline candidates · ~12 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
11.7 months
D/E 1.48 · 0% dilution
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Biomea Fusion, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$86.8M
Cash
$45.1M
Quarterly Burn
$11.7M
Runway
11.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| bmf-219 | Phase 2 |
| BMF-500 | Phase 1 |
| BMF-650 | Phase 1 |
| icovamenib | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
62
Total value held
$37.8M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 8,813,359 | $13.5M |
| vanguard capital management llc | 5,194,600 | $7.9M |
| renaissance technologies llc | 1,312,798 | $2.0M |
| marshall wace, llp | 1,198,551 | $1.8M |
| citadel advisors llc | 903,717 | $1.4M |
| susquehanna international group, llp | 856,665 | $1.3M |
| blackrock, inc. | 641,435 | $981K |
| fideuram - intesa sanpaolo private banking s.p.a. | 557,036 | $852K |
| geode capital management, llc | 548,186 | $839K |
| xtx topco ltd | 530,542 | $812K |
Showing top 10 of 62 institutional holders of Biomea Fusion, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Biomea Fusion, Inc.'s pipeline?
Biomea Fusion, Inc. (BMEA) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Biomea Fusion, Inc.'s lead drug candidate?
Biomea Fusion, Inc.'s most advanced tracked candidate is bmf-219 (Phase 2) for Type 1 Diabetes Mellitus.
What is Biomea Fusion, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Biomea Fusion, Inc. has approximately 11.7 months of cash runway.
What is Biomea Fusion, Inc.'s market capitalization?
Biomea Fusion, Inc.'s market capitalization is approximately $86.8M.
Who is the CEO of Biomea Fusion, Inc.?
Dr. Michael J. M. Hitchcock Ph.D. is the chief executive officer of Biomea Fusion, Inc. (BMEA).
Get the full picture on Biomea Fusion, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.